Yes, treden, that comment about building inventory for "potential market supply" didn't escape me either. I would still suggest that the bigger "tell" was Missling's assertion that they were seriously considering proposing the ongoing OLE as the confirmatory trial for AD as a follow-up to the P2b/3 trial when presumably seeking Accelerated Approval. It would take a lot of balls to suggest that seemingly rather novel approach unless the OLE - with far fewer participants than a typical "confirmatory trial" - was generating very impressive data and unless Dr. Kun Jin had signed off on that concept.
News 
Market Data 
Discover 
